Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Free Cash Flow: 2019-2025

Historic Free Cash Flow for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to -$86.5 million.

  • Beam Therapeutics' Free Cash Flow rose 3.58% to -$86.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$352.4 million, marking a year-over-year decrease of 142.38%. This contributed to the annual value of -$356.2 million for FY2024, which is 94.72% down from last year.
  • Per Beam Therapeutics' latest filing, its Free Cash Flow stood at -$86.5 million for Q3 2025, which was down 8.67% from -$79.6 million recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Free Cash Flow peaked at $203.2 million during Q1 2022, and registered a low of -$120.5 million during Q1 2023.
  • Its 3-year average for Free Cash Flow is -$73.8 million, with a median of -$89.7 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Beam Therapeutics' Free Cash Flow was 505.91% (2022), while the steepest drop was 3,011.54% (2022).
  • Over the past 5 years, Beam Therapeutics' Free Cash Flow (Quarterly) stood at -$11.5 million in 2021, then plummeted by 571.22% to -$77.5 million in 2022, then surged by 269.76% to $131.5 million in 2023, then crashed by 160.34% to -$79.3 million in 2024, then increased by 3.58% to -$86.5 million in 2025.
  • Its Free Cash Flow was -$86.5 million in Q3 2025, compared to -$79.6 million in Q2 2025 and -$106.9 million in Q1 2025.